REPLY TO CRICKET
Cricket this case study describes exactly that scenario although the patient only had one treatment of CF33 anti PD-L1 treatment and withdraw due to rapid disease progression which the authors believe could have been pseudo progression, but will never know as some resolution came after different treatment but is was a stunning result from one treatment but as they say needed more trials.

Maybe we will know soon?

CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study

ClinicalTrials.gov NCT05081492.

CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study - Yuan Yuan, Colt Egelston, Oscar Colunga Flores, Shyambabu Chaurasiya, David Lin, Helen Chang, Leslie Mi Ok Chong, Amanda Seiz, Monil Shah, W. Hans Meisen, Aileen Tang, Norma Martinez, Wichanee Pickett, Mireya Murga, Susan E. Yost, Daphne Stewart, Jianying Zhang, Nicholas Ede, Badri Modi, Jonathan Kessler, Jamie Rand, Yuman Fong, 2023